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outcome is comparable with pelvic exenteration surgery and it is 
better with longer interval between two radiation schedules. 
However, larger series and longer follow-up of clinical outcome and 
late toxicities is required for further validation of current promising 
results. 
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Purpose/Objective: The aim of this retrospective study was to 
investigate treatment results and toxicity profile of reirradiation 
treatment in inoperable patients with first local recurrence of cervical 
or vaginal cancer. Additional analysis of clinical and dosimetric 
parameters was undertaken in order to define prognostic factor in this 
cohort. 
Materials and Methods: Between 1997 and 2011, 20 patients have 
been treated at Brachytherapy Department in Warsaw for recurrent 
cervical (19) or vaginal (1) cancer. All patients were deemed 
inoperable or refused surgery. Median age of patients was 62 years 
(range 26-77). Three patients had adenocarcinoma, 16 - squamous cell 
carcinoma and one- carcinoma solidum undifferentiatum. Three 
patients were treated with combined EBRT and brachytherapy. In 9 
patients brachytherapy was associated with hyperthermia treatment. 
The main technique used in brachytherapy applications was 
interstitial (11 patients), followed by vaginal cylinder (6) or 
intraoperative (3). The median EQD2 dose calculated for reirradiation 
treatment was 48,8Gy (range 25-91), and median cumulative EQD2 
dose calculated for primary and reirratiation treatment was 133,5Gy 
(range 96,8-164,2). Early and late toxicity was scored with RTOG and 
RTOG/EORTC scales respectively. Kaplan-Meier estimates for overall 
survival(OS), disease free survival (DFS) and loco-reginal control (LC) 
were calculated. Mantel-Cox’s method was used to define the 
influence of clinical and dosimetric parameters on OS, DFS, LC and 
toxicity profile.  
Results: The 3-year OS (95%CI) was 68% (44%-91%). The 2-year DFS 
(95% CI) was 42.1% (19.4%-64.8%). The 2-year LC (95% CI) was 45.1% 
(21.6%-68.6%). According to Mantel-Cox’s analysis, the time to first 
local failure ≤12 months and tumour diameter > 3cm were both 
adverse prognostic factors affecting OS (p=0.001, 0,001 respectively), 
DFS (p=0.014,0,013 respectively) and LC (p=0.007, 0,005 
respectively). Acute toxicity was acceptable, with no grade 3-4 
radiation related toxic effects reported. GU and GI grade 3 late 
toxicity was observed in 2 patients (10%) and 1 patient (5%) 
respectively.  
Conclusions: Reirradiation with the use of high quality brachytherapy 
is a treatment option in recurrent cervical and vaginal cancers with 
potential for permanent cure. Low level of severe late complications 
encourages total dose escalationin order to increase the chance of 
cure. According to the results of this analysis patients with local 
recurrence diagnosed during the first year of follow up or tumour 
diameter > 3cm should not be treated with radiotherapy again.  
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Purpose/Objective: Chemoradiotherapy is the standard of care for 
locally advanced head and neck cancer (LAHNC). However, many 
elderly patients are unsuitable for this approach. We report our 
experience of altered fractionated radiotherapy (RT) as a potential 
means of treatment intensification for this population. 
Materials and Methods: A retrospective review was conducted on a 
prospectively assembled cohort of all newly diagnosed LAHNC (stage 
III-IV) in elderly patients (> 70 years old at the diagnosis) treated with 
RT alone in our institution between 1/1/2003 ~ 4/30/2010. RT 
regimens were not randomly assigned and were classified into 3 
categories: a) standard RT (sRT) [70 Gy in 35 fractions over 7 weeks 
(70 Gy/35f/7w)], b) moderated accelerated RT (mRT) over 5 or 6 
weeks (60 Gy/25f/5w, or 70 Gy/35f/6w), and c) very accelerated RT 
(vRT) over 4 weeks (64 Gy/40f/4w, twice daily). Appropriate 
supportive measures were provided during and after RT. Selective use 
of vRT was primarily in patients with good performance status but 
with bulky tumors. Overall survival (OS), locoregional control (LRC), 
distant control (DC), and actuarial late toxicity (>=Grade 3 by 
EORTC/RTOG criteria) were calculated and compared among the sRT, 
mRT and vRT cohorts. Multivariate analysis (MVA) identified predictors 
for OS and LRC. 
Results: A total of 294 patients were included (48 sRT, 178 mRT and 
68 vRT). Disease sites were: oropharynx (113, HPV positive 38, 
negative 32, unascertained 43), larynx (93), oral cavity (33), unknown 
primary (23), hypopharynx (25), and nasal cavity (7). Six patients (2 
sRT and 4 mRT) did not finish the RT and 77 patients (14 sRT, 46 mRT, 
17 vRT) had unplanned breaks during RT. The vRT patients were 
younger (median age: vRT 74.9, sRT 75.2, mRT 76.5 years, p<0.01). 
Smoking pack-years and the proportions of oropharyngeal cancer, T4 
and N2b-N3 category disease were similar among the 3 cohorts. Of the 
183 deaths, 24/35 (69%) sRT, 64/107 (60%) mRT, and 22/41 (53%) vRT 
cases died of their index cancer. 3-year outcomes for the 3 cohorts 
are listed in table 1. MVA revealed mRT was associated with better OS 
(HR 0.62, p=0.02) and LRC (HR 0.49, p<0.01) vs sRT, while vRT was 
also associated with better OS (HR 0.49, p<0.01) and marginally 
improved LRC vs sRT (HR 0.66, p=0.19) when controlling for T- & N-
category, age, smoking pack-years, and disease site. 
 
  
Conclusions: This non-randomized assigned cohort study demonstrates 
an association between altered fractionation RT schedules and 
outcome in elderly patients with LAHNC, without significantly 
increased late toxicity. The benefit of vRT is uncertain, since the 
observations are likely confounded by selection bias (bulkier tumor on 
the one hand and younger fitter patients on the other) and small 
sample size. With appropriate patient selection, altered fractionation 
RT is a valid treatment intensification option for the older population 
in the setting of appropriate supportive management during and 
following RT. 
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Purpose/Objective: To investigate the clinical value of the plasma 
EBV DNA (pEBV DNA) assay in patients with nasopharyngeal carcinoma 
(NPC) after curative treatment. 
